Recent court filings in Memphis challenge widely reported claims that Dr. Sanjeev Kumar performed thousands of biopsies with contaminated equipment — a story that has become a flashpoint in debates over medical-device rules and criminal prosecutions of physicians. The disputed evidence and handling of government data in the case carry immediate consequences for patient access to office-based procedures and for how regulators and prosecutors present technical medical facts to juries.
At the center of the controversy is how government investigators compiled and presented records that prosecutors used to quantify alleged misconduct at Poplar Avenue Clinic. Court documents allege the datasets provided to the defense and to the public contained incomplete information, no patient identifiers and, in some instances, entries attributed to patients who do not appear in clinic records.
Defense filings say procedural totals were inflated by counting a range of administrative items — including denied claims, crossover claims, and clerical rejections — as if each were an performed biopsy. Those counting methods, according to the filings, were repeatedly cited in media accounts and press releases that framed the number of disputed procedures as an indisputable fact.
NRIs in New South Wales: temples offer Hindu puja and Buddhist meditation
Ohio adds former Bhutan refugee Bhuwan Pyakurel to city council
Clinic supply records and staff testimony, however, describe a different picture for the sampling method used in endometrial biopsies. Documents show purchases of more than 40,000 sterile, single-use endometrial pipelles, and multiple employees testified that a new disposible pipelle was used for each patient. The defense notes the jury was not asked to determine whether any particular device was used on a particular patient.
Poplar Avenue Clinic also used reusable hysteroscopes and related instruments that, according to defense evidence, were subject to routine reprocessing. Those materials, the filings say, were reprocessed under established guidance from the Centers for Disease Control and Prevention and according to instructions for use cleared by the Food and Drug Administration for high-level disinfection — practices common in office-based gynecologic care globally.
Questions about expert testimony and agency evidence further complicate the record. Court papers identify several government witnesses whose backgrounds or actions were challenged by the defense:
- Expert credentials: A paid government expert who had not performed office hysteroscopy was allowed to testify about in-office practices.
- State official’s experience: A TennCare deputy chief medical officer had not been in clinic practice for years and was described in filings as having been advised by the state medical board on a re-entry pathway.
- Cooperating witness: A clinician who testified about device reuse admitted similar practices in his own work, received immunity from prosecution and later joined another local clinic.
Materials related to FDA involvement are also cited in the filings. A lead reviewer’s testimony is described as indicating the agency had never cleared a hysteroscope for high-level disinfection — a statement the defense says runs contrary to existing device clearances. The filings further allege that one investigative agent deleted evidence from a personal phone and that a lead reviewer later departed the agency.
Items shown to the jury came from long-term FBI custody, and defense filings emphasize their condition. Many devices were reportedly broken or non-functional after more than a year in evidence storage; some were identified as cystoscopes rather than hysteroscopes, and several had manufacturer safety features designed to prevent reuse.
An independent review by the Tennessee State Medical Board cited in court documents found no professional misconduct by clinic staff. Beyond Dr. Kumar, the board did not recommend charges against other clinicians who collectively performed more than 1,000 procedures at the practice.
Supporters of Dr. Kumar point to his professional recognitions and to the broader public health stakes. Court filings note he was listed as a Top Doctor in 2024 and that the clinic provided expanded access to office-based hysteroscopy and sampling — procedures that can detect endometrial cancer earlier and that are important to care in underserved communities. The case’s criminal sentence — cited as 20 years in United States v. Sanjeev Kumar in filings — has been described by some observers as an example of aggressive prosecution that may chill clinicians’ willingness to offer in-office diagnostics.
Why this matters now: the records unearthed in recent filings show how forensic datasets, evidence custody and interpretation of device guidance can shape public narratives and courtroom outcomes. The episode underscores gaps between clinical practice norms, regulatory language, and how non-clinical actors translate technical material for legal use.
Key disputed points at a glance:
- Data attribution: Government spreadsheets allegedly included entries for non-existent patients and counted rejected claims as procedures.
- Disposable devices: Clinic invoices and testimony document large purchases of single-use pipelles and testify to one-per-patient use.
- Reprocessing standards: Reusable hysteroscopes were reportedly disinfected following CDC/FDA guidance and device instructions for use.
- Evidence integrity: Devices admitted at trial were handled in long-term FBI custody and some were damaged or misidentified.
- Regulatory testimony: FDA reviewer testimony and evidence handling are criticized as inconsistent with public device clearances.
The case leaves several practical questions for health systems, regulators and prosecutors: how to ensure data supplied in investigations is auditable and clinically interpretable; how to present nuanced device guidance in court without oversimplifying; and how to protect access to office-based diagnostics while enforcing patient safety. As the legal record continues to be reviewed, policy discussions prompted by these filings may determine whether clearer standards or new oversight practices are adopted.
